Oramed Pharmaceuticals Inc Asset Resilience Ratio
Oramed Pharmaceuticals Inc asset resilience ratio. Oramed Pharmaceuticals Inc (ORMP) has an Asset Resilience Ratio of 19.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Oramed Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oramed Pharmaceuticals Inc (2008–2025)
Asset resilience ratio of Oramed Pharmaceuticals Inc from 2008 to 2025. This chart shows how Oramed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Oramed Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oramed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Oramed Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $52.64 Million | 19.58% |
| Total Liquid Assets | $52.64 Million | 19.58% |
Asset Resilience Insights
- Good Liquidity Position: Oramed Pharmaceuticals Inc maintains a healthy 19.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Oramed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Oramed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Oramed Pharmaceuticals Inc Asset Resilience Ratio by Year (2008–2025)
Oramed Pharmaceuticals Inc asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Oramed Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.63% | $79.95 Million | $230.86 Million | -21.73pp |
| 2024-12-31 | 56.36% | $87.51 Million | $155.28 Million | -13.01pp |
| 2023-12-31 | 69.37% | $152.99 Million | $220.55 Million | -1.94pp |
| 2022-12-31 | 71.30% | $115.26 Million | $161.64 Million | +58.10pp |
| 2021-12-31 | 13.20% | $16.89 Million | $128.00 Million | -32.96pp |
| 2020-12-31 | 46.16% | $20.60 Million | $44.63 Million | -37.36pp |
| 2019-12-31 | 83.53% | $28.95 Million | $34.66 Million | +29.80pp |
| 2018-12-31 | 53.73% | $25.47 Million | $47.40 Million | +12.01pp |
| 2017-12-31 | 41.73% | $16.15 Million | $38.71 Million | -21.57pp |
| 2016-12-31 | 63.29% | $27.11 Million | $42.83 Million | +10.11pp |
| 2015-12-31 | 53.18% | $14.02 Million | $26.35 Million | -36.39pp |
| 2014-12-31 | 89.57% | $19.53 Million | $21.80 Million | +17.94pp |
| 2013-12-31 | 71.63% | $6.20 Million | $8.66 Million | +67.84pp |
| 2012-12-31 | 3.78% | $200.31K | $5.29 Million | -5.11pp |
| 2011-12-31 | 8.89% | $384.56K | $4.33 Million | +2.00pp |
| 2010-12-31 | 6.89% | $100.00K | $1.45 Million | -23.77pp |
| 2009-12-31 | 30.66% | $1.00 Million | $3.26 Million | -18.88pp |
| 2008-12-31 | 49.54% | $2.73 Million | $5.51 Million | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more